CTOR – citius oncology, inc. (US:NASDAQ)
Stock Stats
News
Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update [Yahoo! Finance]
Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update
Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025 [Yahoo! Finance]
Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update
Citius Oncology, Inc. (NASDAQ: CTOR) is now covered by analysts at Maxim Group. They set a "buy" rating and a $3.00 price target on the stock.
Form 8-K CITIUS ONCOLOGY, INC. For: Feb 14
Form 10-Q CITIUS ONCOLOGY, INC. For: Dec 31
Form PRE 14C CITIUS ONCOLOGY, INC. For: Feb 12
Form 8-K CITIUS ONCOLOGY, INC. For: Feb 06
Form 10-K/A CITIUS ONCOLOGY, INC. For: Sep 30
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.